Pfizer Inc. $PFE Shares Sold by Midland Wealth Advisors LLC

Midland Wealth Advisors LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 13.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 22,803 shares of the biopharmaceutical company’s stock after selling 3,461 shares during the quarter. Midland Wealth Advisors LLC’s holdings in Pfizer were worth $553,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Aspen Wealth Strategies LLC lifted its stake in Pfizer by 9.2% during the 2nd quarter. Aspen Wealth Strategies LLC now owns 9,983 shares of the biopharmaceutical company’s stock worth $242,000 after acquiring an additional 841 shares in the last quarter. Samalin Investment Counsel LLC grew its holdings in Pfizer by 2.2% during the 2nd quarter. Samalin Investment Counsel LLC now owns 30,274 shares of the biopharmaceutical company’s stock worth $734,000 after acquiring an additional 657 shares in the last quarter. Vise Technologies Inc. purchased a new position in Pfizer in the second quarter valued at $5,615,000. Cahill Financial Advisors Inc. raised its position in shares of Pfizer by 23.1% during the 2nd quarter. Cahill Financial Advisors Inc. now owns 21,767 shares of the biopharmaceutical company’s stock worth $528,000 after acquiring an additional 4,087 shares in the last quarter. Finally, Alpha Cubed Investments LLC lifted its position in shares of Pfizer by 2.3% during the 2nd quarter. Alpha Cubed Investments LLC now owns 23,540 shares of the biopharmaceutical company’s stock worth $571,000 after buying an additional 527 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several research analyst reports. Sanford C. Bernstein reissued a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a report on Friday, October 31st. Morgan Stanley reduced their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. UBS Group reissued a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $28.18.

Pfizer Stock Down 1.6%

Shares of PFE opened at $24.45 on Monday. The company’s fifty day moving average is $24.74 and its two-hundred day moving average is $24.38. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm has a market cap of $138.99 billion, a PE ratio of 13.00, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.